Understanding tissue response in anal cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to enhance the understanding of tumor biology in anal cancer patients by examining the tumor microenvironment, cellular interactions between tumors and immune cells, and the gene and protein expression in tumor and surrounding tissues. Eligible participants include adults with newly diagnosed or recurrent anal cancer, who will provide biopsies and blood samples during diagnostic and follow-up examinations. The study is conducted at Sahlgrenska University Hospital, where patients will be monitored throughout their treatment process.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Newly diagnosed or recurrent anal cancer

Exclusion Criteria:

* No diagnosis of anal cancer, contraindication to biopsies and blood samples

Where it's running

• Dept. of Surgery, Sahlgrenska University Hospital/Ostra
  Gothenburg, Sweden Recruiting
• Sahlgrenska University Hospital
  Gothenburg, Sweden Recruiting

Study contacts

• Study coordinator: Eva Angenete PI, Professor
• Email: eva.angenete@gu.se
• Phone: +46760514441

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Retifanlimab after chemoradiation for anal cancer

  This study tests whether retifanlimab can help people with anal squamous cell carcinoma who have completed chemoradiation and still have residual disease.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07927998

• Irreversible Electroporation for Recurrent Pelvic Tumors

  This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT07782164

• HPV DNA-guided chemoradiation with Retifanlimab for locally advanced anal cancer

  This study tests whether adjusting chemoradiation doses based on HPV ctDNA results and adding Retifanlimab after CRT can improve outcomes for adults with new, locally advanced anal cancer.

  Recruiting Phase 2 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07425054

• Gynecological and sexual health after radiotherapy for anal cancer.

  See if vaginal problems and changes in sexual health are linked to radiation dose in women treated with chemoradiotherapy for anal cancer 6–36 months after treatment.

  Recruiting at 3 sites Aarhus University Hospital · Aarhus and 2 other locations · NCT07296237

• Self-sampling to improve anal lesion outcomes

  This study will test whether people at higher risk for anal cancer will use a self-collected anal swab and whether that increases follow-up cytology and high-resolution anoscopy (HRA) appointment attendance.

  Recruiting at 3 sites Medical College of Wisconsin · Chicago, Illinois and 2 other locations · NCT07192055

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.